Immunocore Holdings plc reports commercial and clinical developments for a biotechnology issuer whose Nasdaq-listed ADSs represent ordinary shares. The company uses its ImmTAX TCR bispecific immunotherapy platform across oncology, infectious disease and autoimmune programs, with KIMMTRAK (tebentafusp-tebn) approved for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia and the United Kingdom.
Recurring updates cover KIMMTRAK sales and long-term survival data, lifecycle-management studies in uveal and cutaneous melanoma, the PRAME-A02 candidate brenetafusp, earlier ImmTAX candidates, HIV functional-cure research, autoimmune disease pipeline activity, financial results, investor presentations and R&D governance changes.
Immunocore Holdings Plc (Nasdaq: IMCR) announced its participation in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference scheduled for March 16, 2022, at 9:20 a.m. ET. The event will be available via live webcast on Immunocore’s website, with a replay offered for a limited time. Immunocore specializes in pioneering T cell receptor bispecific immunotherapies, aiming to treat diseases like cancer and autoimmune disorders. Its lead product, KIMMTRAK, has been approved by the U.S. FDA for treating metastatic uveal melanoma, a condition showing historical resistance to other therapies.
Immunocore reported full-year 2021 financial results, highlighting the FDA approval of KIMMTRAK® for unresectable or metastatic uveal melanoma, marking a significant milestone as the first TCR therapy approved for solid tumors. The company had a cash position of approximately $321 million as of December 31, 2021. Revenue for 2021 was $35.8 million, a decrease from the previous year, while total operating loss reached $182.5 million. The company plans to report data on its clinical candidates targeting PRAME and MAGE-A4 in 2022.
Immunocore announced a positive opinion from the CHMP recommending approval of KIMMTRAK® (tebentafusp) for treating unresectable or metastatic uveal melanoma (mUM) in Europe. If sanctioned by the EMA, KIMMTRAK would be the first approved therapy in this indication. The treatment showed significant overall survival benefits in clinical trials, with a hazard ratio of 0.51. KIMMTRAK has already received FDA approval in the U.S. Offering a new hope for patients, this therapy is part of Immunocore’s innovative T cell receptor treatment platform.
Immunocore Holdings Plc (Nasdaq: IMCR) will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 12:00 p.m. ET. The biotechnology company specializes in T cell receptor (TCR) bispecific immunotherapies to treat various diseases, including cancer. Their leading treatment, KIMMTRAK, is FDA-approved for patients with unresectable metastatic uveal melanoma. The presentation will be available via webcast on the company's website, along with a replay for a limited time.
Immunocore has received FDA approval for KIMMTRAK® (tebentafusp-tebn), the first therapy for unresectable or metastatic uveal melanoma (mUM). This groundbreaking treatment shows a median overall survival of nearly 22 months, with a hazard ratio of 0.51. The approval marks several milestones, including the first T cell receptor therapeutic to gain regulatory approval. The company aims to commercialize KIMMTRAK in the U.S. shortly, having established an early access program for patients. Immunocore's CEO highlighted this achievement as a significant step toward addressing the unmet needs in treating mUM.
Immunocore Holdings Plc (Nasdaq: IMCR) will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 7:30 a.m. ET. The conference will be held virtually, and the presentation along with a Q&A session will be streamed live on Immunocore’s website. Immunocore is known for its innovative T cell receptor (TCR) bispecific immunotherapies that target diseases like cancer and autoimmune disorders. The company's leading therapeutic candidate, tebentafusp, has shown promise in extending overall survival in metastatic uveal melanoma.
Immunocore Holdings Plc (Nasdaq: IMCR) has announced initial Phase 1 data for its bispecific T cell engager, IMC-C103C, targeting MAGE-A4, showing clinical activity in ovarian cancer and head and neck squamous cell carcinoma (HNSCC). Among 44 patients in the trial, there were confirmed durable responses, even in heavily pre-treated patients with low MAGE-A4 expression. The safety profile was manageable, with reversible adverse events primarily related to cytokine release syndrome. An expansion arm in high-grade serous ovarian cancer has been initiated at a dose of 140 micrograms.
Acacia Research reported significant financial developments for Q3 2021, highlighted by a nearly $120 million gain from the IPO of Oxford Nanopore. Pro forma book value increased to $6.31 per share, while cash and investments soared to $605.1 million. Gross revenue was $1.6 million, a decline from $19.5 million year-over-year, and the operating loss grew to $12.7 million. Notably, net income surged to $80.2 million or $0.86 per diluted share, compared to $29.2 million or $0.32 per share last year. A conference call is scheduled for November 15, 2021.
Immunocore will participate in a fireside chat at the Jefferies London Healthcare Conference from November 16-19, 2021. The on-demand presentation will be accessible starting November 18, 2021. As a late-stage biotechnology firm, Immunocore develops T cell receptor bispecific immunotherapies to treat diseases like cancer and autoimmune disorders. Their lead candidate, tebentafusp, demonstrated significant survival benefits in metastatic uveal melanoma during clinical trials.
Immunocore (IMCR) reported its Q3 2021 financial results, highlighting the acceptance of its Biologics License Application for tebentafusp in metastatic uveal melanoma, with the FDA setting a PDUFA date of February 23, 2022. The company has treated over 150 patients through an early access program. Financially, revenue fell to £5.9 million from £6.7 million year-over-year, while operating loss increased to £31 million, largely due to rising employee costs. As of September 30, 2021, cash reserves were approximately $346 million.